Volume: 13 Issue: 2
Year: 2025, Page: 128-133, Doi: https://doi.org/10.47799/pimr.1302.25.17
Received: May 30, 2025 Accepted: June 17, 2025 Published: Aug. 19, 2025
Background: Guillain-Barré Syndrome (GBS) has a variable clinical course. Limited data are available on therapeutic decisions in patients with mild disease severity. Methods: We conducted a retrospective, record-based observational study of 32 patients with mild GBS (defined as Hughes disability grade ≤ 2) admitted to SVP Institute of Medical Sciences & Research (Ahmedabad) from August 2016 to July 2019. Patients who worsened clinically during hospitalization (i.e., an increase by ≥1 Hughes grade) were treated with intravenous immunoglobulin (IVIG) or plasmapheresis (PLEX). Demographic, clinical, cerebrospinal fluid (CSF), and electrodiagnostic parameters were analyzed. Outcomes were assessed at 1-month post-discharge. Statistical tests included Fisher’s exact test and logistic regression. Results: Among 32 patients (mean age 31.3 years; M: F ratio 3.6:1), nine experienced clinical worsening and required treatment. Early presentation (<7 days from symptom onset) was significantly associated with deterioration (p < 0.001). Bulbar and bifacial weakness were more common among treated patients. Regression analysis showed symptom onset-to-hospitalization duration was the only independent predictor of worsening (OR 3.74, p = 0.032). At 1 month, 66.7% of treated patients and 34.8% of untreated patients had a good outcome (Hughes ≤1). Conclusion: Mild GBS patients presenting within 7 days were more likely to deteriorate during admission in this retrospective cohort. Prospective studies that account for time-at-risk and use validated risk scores are needed to guide treatment decisions.
Keywords: Mild GBS, Outcome, Hughes scale, MRC sum score, Retrospective study
Hughes, R A C, Newsom-Davis, J M, Perkin, G D & Pierce, J M . 1978. Controlled trial of prednisolone in acute polyneuropathy. The Lancet 312(8093):750–753.
Hughes, R A C, Swan, A V & Doorn, P A Van . 2014. Intravenous immunoglobulin for Guillain‐Barré syndrome. Cochrane Database of Systematic Reviews 2014(9):CD002063.
Koningsveld, R Van, Doorn, P A Van, Schmitz, P I M, Ang, C W & Meché, F G A Van der . 2000. Mild forms of Guillain-Barré syndrome in an epidemiologic survey in the Netherlands. Neurology 54(3):620–625.
Koningsveld, R Van, Schmitz, P I M, Ang, C W, Groen, J, Osterhaus, A D M E, Meché, F G A Van Der & Doorn, P A Van . 2002. Infections and course of disease in mild forms of Guillain–Barré syndrome. Neurology 58(4):610–614.
Hughes, R A C, Swan, A V, Raphael, J C, Annane, D, Koningsveld, R van & Doorn, P A van . 2007. Immunotherapy for Guillain-Barre syndrome: a systematic review. Brain 130(9):2245–2257.
Verboon, Christine, Harbo, Thomas, Cornblath, David R, Hughes, Richard A C, Doorn, Pieter A van, Lunn, Michael P, Gorson, Kenneth C, Barroso, Fabio, Kuwabara, Satoshi, Galassi, Giuliana, Lehmann, Helmar C, Kusunoki, Susumu, Reisin, Ricardo C, Binda, Davide, Cavaletti, Guido & Jacobs, Bart C . 2021. Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: an international observational study. Journal of Neurology, Neurosurgery & Psychiatry 92(10):1080–1088.
1978. National Institute of Neurological and Communicative Disorders and Stroke ad hoc Committee. Criteria for diagnosis of Guillain-Barré syndrome. Annals of Neurology 3(6):565–566.
Asbury, Arthur K & Cornblath, David R . 1990. Assessment of current diagnostic criteria for Guillain–Barré syndrome. Annals of Neurology 27(S1):S21–S24.
Hadden, R D M, Cornblath, D R, Hughes, R A C, Zielasek, J, Hartung, H P, Toyka, K V, Swan, A V & . 1998. Electrophysiological classification of guillain‐barré syndrome: Clinical associations and outcome. Annals of Neurology 44(5):780–788.
Walgaard, C, Lingsma, H F, Ruts, L, Doorn, P A van, Steyerberg, E W & Jacobs, B C . 2011. Early recognition of poor prognosis in Guillain-Barré syndrome. Neurology 76(11):968–975.
Walgaard, Christa, Lingsma, Hester F, Ruts, Liselotte, Drenthen, Judith, Koningsveld, Rinske van, Garssen, Marcel J P, Doorn, Pieter A van, Steyerberg, Ewout W & Jacobs, Bart C . 2010. Prediction of respiratory insufficiency in Guillain‐Barré syndrome. Annals of Neurology 67(6):781–787.
Green, Deborah M & Ropper, Allan H . 2001. Mild Guillain-Barré Syndrome. Archives of Neurology 58(7):1098–1101.
Weiss, Nicolas, Marois, Clémence, Guennec, Loic Le, Rohaut, Benjamin & Demeret, Sophie . 2025. Critical insights for intensivists on Guillain-Barré syndrome. Annals of Intensive Care 15(1):67.
Verboon, Christine, Doorn, Pieter A van & Jacobs, Bart C . 2017. Treatment dilemmas in Guillain-Barré syndrome. Journal of Neurology, Neurosurgery & Psychiatry 88(4):346–352.
Rahaman, H, Rahman, H Z, Emran, M M & Rahman, M A . 2024. Association of CSF total protein with clinical heterogeneity, disease severity and electrophysiological pattern in GBS patients. Mymensingh Medical Journal 33(2):496–500.
Korinthenberg, Rudolf, Schessl, Joachim, Kirschner, Janbernd & Mönting, Jürgen Schulte . 2005. Intravenously Administered Immunoglobulin in the Treatment of Childhood Guillain-Barré Syndrome: A Randomized Trial. Pediatrics 116(1):8–14.
1997. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. An appropriate number of plasma exchanges in Guillain-Barré syndrome. Annals of Neurology 41(3):298–306.
Verboon, Christine, Doets, Alex Y, Galassi, Giuliana, Davidson, Amy, Waheed, Waqar & Péréon, Yann . 2019. Current treatment practice of Guillain-Barré syndrome. Neurology 93(1):e59–e76.
©2025 (Pranav B Joshi) et al. This is an open-access journal, and articles are distributed under the terms of the Creative Commons Attribution License CC-BY 4.0. (https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are credited.
Joshi PB, Shah SD, Patel MA, Mirche K, Trivedi S, Shah DS. Clinical Course and Short-Term Outcome of Mild Guillain-Barré Syndrome: A Retrospective Observational Study from Western India. Perspectives in Medical Research. 2025;13(2):128-133 DOI:10.47799/pimr.1302.25.17